On Friday, Pliant Therapeutics Inc (NASDAQ: PLRX) was 14.11% up from the session before settling in for the closing price of $1.63. A 52-week range for PLRX has been $1.10 – $16.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -78.30%. When this article was written, the company’s average yearly earnings per share was at 25.31%. With a float of $54.04 million, this company’s outstanding shares have now reached $61.39 million.
Pliant Therapeutics Inc (PLRX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Pliant Therapeutics Inc stocks. The insider ownership of Pliant Therapeutics Inc is 11.97%, while institutional ownership is 82.30%. The most recent insider transaction that took place on Jan 17 ’25, was worth 587,150. In this transaction President and CEO of this company sold 52,419 shares at a rate of $11.20, taking the stock ownership to the 430,517 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Financial Officer sold 20,148 for $11.20, making the entire transaction worth $225,680. This insider now owns 262,608 shares in total.
Pliant Therapeutics Inc (PLRX) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.95 earnings per share (EPS) during the time that was better than consensus figure (set at -0.98) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 25.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.80% during the next five years compared to -78.30% drop over the previous five years of trading.
Pliant Therapeutics Inc (NASDAQ: PLRX) Trading Performance Indicators
You can see what Pliant Therapeutics Inc (PLRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 12.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.39, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach -1.82 in one year’s time.
Technical Analysis of Pliant Therapeutics Inc (PLRX)
Looking closely at Pliant Therapeutics Inc (NASDAQ: PLRX), its last 5-days average volume was 1.06 million, which is a drop from its year-to-date volume of 1.68 million. As of the previous 9 days, the stock’s Stochastic %D was 84.49%.
During the past 100 days, Pliant Therapeutics Inc’s (PLRX) raw stochastic average was set at 96.05%, which indicates a significant increase from 93.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1109 in the past 14 days, which was lower than the 0.1116 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5030, while its 200-day Moving Average is $4.7348. However, in the short run, Pliant Therapeutics Inc’s stock first resistance to watch stands at $1.9633. Second resistance stands at $2.0667. The third major resistance level sits at $2.2433. If the price goes on to break the first support level at $1.6833, it is likely to go to the next support level at $1.5067. Should the price break the second support level, the third support level stands at $1.4033.
Pliant Therapeutics Inc (NASDAQ: PLRX) Key Stats
There are 61,388K outstanding shares of the company, which has a market capitalization of 114.18 million. As of now, sales total 0 K while income totals -210,300 K. Its latest quarter income was 0 K while its last quarter net income were -43,300 K.
